Stock 002422 SICHUAN KELUN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sichuan Kelun Pharmaceutical Co., Ltd.

Equities

002422

CNE100000PW7

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 05/05/2024 BST 		5-day change 1st Jan Change
34 CNY +0.15% Intraday chart for Sichuan Kelun Pharmaceutical Co., Ltd. +4.94% +17.04%
04-25 Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI
04-25 Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 33,821 27,803 26,621 37,335 42,829 54,090 - -
Enterprise Value (EV) 1 42,133 36,599 33,785 42,634 45,047 55,457 54,883 55,838
P/E ratio 36.1 x 33.5 x 24.3 x 23.1 x 18.3 x 18.7 x 17.1 x 15.1 x
Yield 1.81% 1.64% 2.25% 2.31% 2.75% 1.77% 1.88% 3.02%
Capitalization / Revenue 1.92 x 1.69 x 1.54 x 1.97 x 2 x 2.32 x 2.14 x 1.9 x
EV / Revenue 2.39 x 2.22 x 1.96 x 2.25 x 2.1 x 2.38 x 2.17 x 1.96 x
EV / EBITDA 17.9 x 16.9 x 13.3 x 12.7 x 9.26 x 11.6 x 10.5 x 9.46 x
EV / FCF - - - - 12,621,250 x - - -
FCF Yield - - - - 0% - - -
Price to Book 2.56 x 2.07 x 1.95 x 2.45 x 2.23 x 2.46 x 2.27 x 2.06 x
Nbr of stocks (in thousands) 1,439,786 1,430,179 1,406,277 1,403,045 1,474,304 1,590,876 - -
Reference price 2 23.49 19.44 18.93 26.61 29.05 34.00 34.00 34.00
Announcement Date 27/02/20 14/04/21 07/01/22 13/04/23 11/04/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 17,636 16,464 17,277 18,913 21,454 23,299 25,285 28,493
EBITDA 1 2,352 2,171 2,533 3,363 4,865 4,762 5,239 5,903
EBIT 1 1,277 1,010 1,320 2,199 3,654 3,845 4,454 5,346
Operating Margin 7.24% 6.13% 7.64% 11.63% 17.03% 16.5% 17.62% 18.76%
Earnings before Tax (EBT) 1 1,256 955 1,178 2,071 3,580 3,737 4,176 4,951
Net income 1 937.9 829.4 1,103 1,709 2,456 2,832 3,087 3,499
Net margin 5.32% 5.04% 6.38% 9.03% 11.45% 12.16% 12.21% 12.28%
EPS 2 0.6500 0.5800 0.7800 1.150 1.590 1.820 1.994 2.253
Free Cash Flow - - - - 3,569 - - -
FCF margin - - - - 16.64% - - -
FCF Conversion (EBITDA) - - - - 73.37% - - -
FCF Conversion (Net income) - - - - 145.32% - - -
Dividend per Share 2 0.4250 0.3188 0.4260 0.6160 0.8000 0.6034 0.6400 1.026
Announcement Date 27/02/20 14/04/21 07/01/22 13/04/23 11/04/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4,591 4,482 4,643 4,734 5,054 5,602 5,132 5,009 5,711 6,219 5,801 5,859 5,685 6,471 -
EBITDA - - - - - - - - - - - - - - -
EBIT 388.9 335.2 763.3 756.5 345.5 1,123 754.5 719.9 1,057 - - - - - -
Operating Margin 8.47% 7.48% 16.44% 15.98% 6.84% 20.05% 14.7% 14.37% 18.5% - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - - - -
Net income 1 - - - - - - - - 492.8 1,026 604.6 569.2 555.1 - -
Net margin - - - - - - - - 8.63% 16.5% 10.42% 9.72% 9.77% - -
EPS 2 0.1800 0.2000 0.4000 0.3500 0.2000 0.5200 0.3900 0.3600 0.3200 0.6700 0.5892 0.5285 0.1083 0.9400 -
Dividend per Share 2 - - - - - - - - - - 0.8601 - - - 0.9000
Announcement Date 07/01/22 18/04/22 29/08/22 30/10/22 13/04/23 25/04/23 29/08/23 30/10/23 11/04/24 24/04/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 8,313 8,797 7,164 5,299 2,219 1,368 793 1,748
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 3.534 x 4.052 x 2.828 x 1.575 x 0.4561 x 0.2872 x 0.1513 x 0.2961 x
Free Cash Flow - - - - 3,569 - - -
ROE (net income / shareholders' equity) 7.21% 6.25% 8.07% 11.7% 14.1% 12.9% 13.5% 13.9%
ROA (Net income/ Total Assets) 3.08% 2.61% 3.45% 5.2% 10.3% 7.2% 7.75% 9.3%
Assets 1 30,420 31,729 31,959 32,829 23,744 39,337 39,836 37,625
Book Value Per Share 2 9.160 9.380 9.720 10.90 13.00 13.80 15.00 16.50
Cash Flow per Share 2 1.540 1.540 2.000 2.200 3.560 2.290 2.410 2.700
Capex 1 1,297 1,225 983 883 1,768 1,294 1,366 1,415
Capex / Sales 7.35% 7.44% 5.69% 4.67% 8.24% 5.55% 5.4% 4.96%
Announcement Date 27/02/20 14/04/21 07/01/22 13/04/23 11/04/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Sichuan Kelun Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
34 CNY
Average target price
42.04 CNY
Spread / Average Target
+23.65%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SICHUAN KELUN PHARMACEUTICAL CO., LTD. Stock Sichuan Kelun Pharmaceutical Co., Ltd.
+17.04% 7.46B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+31.13% 662B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.96% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.27% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.03% 323B
ABBVIE INC. Stock AbbVie Inc.
+4.74% 289B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.81% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-10.63% 194B
AMGEN INC. Stock Amgen Inc.
+4.11% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002422 Stock
  4. Financials Sichuan Kelun Pharmaceutical Co., Ltd.